Technology

In vitro production

After Köhler & Milstein's discovery of hybridomas producing monoclonal antibodies in 1975, production was initially done as ascites. Hollow fibre technology has developed over the same period, and has over the last decade given us an excellent alternative to using production animals. Several European countries have banned the use of animals/ascites for antibody production, and also the US is changing in this direction, proving that hollow fibre technology is a very reasonable choice.

Hollow fibre technology

All Diatec Monoclonals in vitro productions are carried out in membrane based or hollow fibre production systems. This ensures that a high number of cells in a relatively small production chamber is supplied with a large volume of medium. Addition of nutrients and removing waste products occur efficiently and resembles a living organism's way of supporting the cells by ensuring optimal growth conditions. Simultaneously, the antibody concentration in the system is increased up to 50x compared to traditional cell culture systems, which results in cost efficient purification and down-stream processing. Another advantage of in vitro production is the yield of a pure product, without animal contaminants, and highly reproducible from batch to batch.

Literature selections

CL1000 Links:

Integra Celline CL1000 information
    
    www.integra-biosciences.com/celline_1_e.html

Publications by Integra Biosciences on membrane technology and CL1000 systems

     www.integra-biosciences.com/celline_7_e.html